Results 41 to 50 of about 4,295 (215)

Personalized Estimate of Chemotherapy-Induced Nausea and Vomiting: Development and External Validation of a Nomogram in Cancer Patients Receiving Highly/Moderately Emetogenic Chemotherapy. [PDF]

, 2016
Chemotherapy-induced nausea and vomiting (CINV) is presented in over 30% of cancer patients receiving highly/moderately emetogenic chemotherapy (HEC/MEC).
Chan, Alexandre, Chen, Likun, Hu, Zhihuang, Huang, Yan, Keefe, Dorothy, Liang, Wenhua, Ma, Yuxiang, Xue, Cong, Yang, Yunpeng, Zhang, Li, Zhao, Hongyun, Zhao, Yuanyuan   +11 more
core   +2 more sources

Comparative Study Between Fosaprepitant and Palonosetron in the Prophylaxis of Postoperative Nausea and Vomiting in Women Undergoing Laparoscopic Cholecystectomy: Prospective, Randomized and Double-Blind Study

Frontiers in Pharmacology, 2022
Objective: To test the hypothesis that the single use of fosaprepitant is not inferior to the use of palonosetron as antiemetic prophylaxis in the first 48 h after surgery in women undergoing laparoscopic cholecystectomy.Method: Eighty-eight nonsmoking ...
Estêvão Luiz Carvalho Braga, Nubia Verçosa, Ismar Lima Cavalcanti   +2 more
doaj   +1 more source

Effects of palonosetron and ondansetron on preventing nausea and vomiting after laparoscopic surgery

Journal of International Medical Research, 2018
Background This meta-analysis was performed to evaluate the efficacy and safety of palonosetron and ondansetron in preventing postoperative nausea and vomiting (PONV) in patients undergoing laparoscopic surgery with general anesthesia.
Qili Liu, Chengmao Zhou, Zeqing Bao, Yu Zhu   +3 more
doaj   +1 more source

Subchronic vortioxetine enhances cortical activity [PDF]

, 2016
Vortioxetine (VOR) is a multimodal antidepressant drug. VOR is a 5-HT3-R, 5-HT7-R and 5-HT1D-R antagonist, 5-HT1B-R partial agonist, 5-HT1A-R agonist, and serotonin transporter (SERT) inhibitor.
Artigas, Francesc, Celada, Pau, Riga, Maurizio, Sánchez, Connie, Teruel-Martí, Vicent   +4 more
core   +1 more source

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of 5‐HT3 Receptor Antagonists: 2026 Update

Clinical Pharmacology &Therapeutics, EarlyView.
5‐hydroxytryptamine type 3 (5‐HT3) receptor antagonists are used to treat nausea and vomiting and in the prevention of chemotherapy‐induced, radiation‐induced, and postoperative nausea and vomiting. Most of the 5‐HT3 receptor antagonists (i.e., ondansetron, tropisetron, dolasetron, palonosetron, and ramosetron) are metabolized by CYP2D6, but the extent
Claire Moore, Melissa S. Bourque, Andreas Halman, José A. G. Agúndez, Cynthia A. Prows, Keiko Hikino, Matthias Schwab, Carolyn J. Oxencis, Dharmisha Chauhan, Meta H.M. Diekstra, Susie E. Long, Gillian C. Bell, Andrea Gaedigk, Michelle Whirl‐Carrillo, Teri E. Klein, Kelly E. Caudle, Rachel Conyers   +16 more
wiley   +1 more source

Comparison of palonosetron and ondansetron to prevent postoperative nausea and vomiting in women using intravenous patient-controlled analgesia [PDF]

Anesthesia and Pain Medicine, 2020
Background We compared the effects of palonosetron with ondansetron for preventing postoperative nausea and vomiting (PONV) during the first 24 h after surgery in women receiving intravenous patient-controlled analgesia (IV-PCA) with fentanyl for pain ...
Jae Hwa Yoo, In Suk Jeon, Ji Won Chung, Jae Hoon Ryoo, Gyu Wan You, Soon Im Kim   +5 more
doaj   +1 more source

Chemotherapy-induced nausea and vomiting: A narrative review to inform dietetics practice [PDF]

, 2016
Chemotherapy-induced nausea and vomiting (CINV) are common nutrition-impact symptoms experienced by cancer patients. They exert a detrimental effect on dietary intake, risk of malnutrition and quality of life.
Isenring, Liz, Kiss, Nicole, Marx, Wolfgang, McCarthy, Alexandra L., McKavanagh, Dan   +4 more
core   +3 more sources

Multi‐omics Analysis Reveals the Correlation of Gut Microbiota and Metabolites With Thalidomide Treatment for Chemotherapy‐Induced Nausea and Vomiting in Small Cell Lung Cancer

Biotechnology Journal, Volume 21, Issue 4, April 2026.
Graphical Abstract and Lay Summary We characterize the gut microbiota signatures associated with Thalidomide treatment in small cell lung cancer patients experiencing chemotherapy‐induced nausea and vomiting. The analysis reveals significant changes in specific genera, linking microbial composition to symptom management. ABSTRACT Small cell lung cancer
Qiang‐Guo Sun, Dan Zang, Yu Xin, Jia Cui, Xu Han, Jun Chen   +5 more
wiley   +1 more source

Concomitant palonosetron ameliorates cisplatin-induced nephrotoxicity, nausea, and vomiting: a retrospective cohort study and pharmacovigilance analysis

Journal of Pharmaceutical Health Care and Sciences, 2022
Background Cisplatin (CDDP)-induced nephrotoxicity is the most important complication of CDDP treatment. 5-Hydroxytryptamine type 3 receptor antagonists (5-HT3RAs) are widely used to prevent chemotherapy-induced nausea and vomiting (CINV).
Miho Takemura, Kenji Ikemura, Masayoshi Kondo, Fumihiro Yamane, Mikiko Ueda, Masahiro Okuda   +5 more
doaj   +1 more source

Effects of a self-management program on antiemetic-induced constipation during chemotherapy among breast cancer patients: a randomized controlled clinical trial. [PDF]

, 2016
Research on patient-reported outcomes indicates that constipation is a common adverse effect of chemotherapy, and the use of 5-hydroxytryptamine (serotonin; 5HT3) receptor antagonists aggravates this condition. As cancer patients take multiple drugs as a
Arai, Hidenori, Hanai, Akiko, Ishiguro, Hiroshi, Mitani, Akira, Sozu, Takashi, Tsuboyama, Tadao, Tsuda, Moe   +6 more
core   +1 more source